Eli Lilly's Baricitinib Evaluated for Safety in Pediatric sJIA Patients
Eli Lilly is conducting a study to assess the safety and efficacy of baricitinib in children with systemic juvenile idiopathic arthritis.
Indication
Clinical and regulatory intelligence for Systemic Juvenile Idiopathic Arthritis with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.